36 papers
The 2016 edition of the Journal of Clinical Oncology featured 36 papers with a strong emphasis on diagnostic imaging and prostate cancer management. Research frequently explored the utility of multiparametric MRI and fusion-guided biopsies, particularly in biopsy-naive populations and for active surveillance. Prolific contributors during this year included Arvin K. George, Barış Türkbey, Bradford J Wood, and Peter A. Pinto, whose work often focused on refining diagnostic techniques for urologic malignancies.
Beyond imaging, the journal addressed public health trends and prognostic modeling. Studies examined enrollment disparities in lung cancer clinical trials between 1990 and 2012 and investigated serum microRNAs as potential early detection markers. Other research analyzed prognostic factors in Hodgkin’s lymphoma and the prevalence of autoimmune comorbidities in patients with metastatic melanoma. Additionally, the year’s publications included efforts to predict post-treatment outcomes, such as erectile function recovery following radiotherapy. This collection reflects a focus on integrating advanced imaging technology with clinical outcomes and epidemiological analysis.
Top Research Directions
The 15 research directions with Journal of Clinical Oncology 2016 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.
Download all directions as CSV
Institutions
Institutions credited by Journal of Clinical Oncology 2016 papers: a paper credits every institution named in its affiliations, once. 16 institutions share 3 credited papers.
Download all institutions as CSV
About this data
Papers. Journal of Clinical Oncology 2016 lists 36 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.
Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.
Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 3 of 36 papers (8.3%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.
Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Clinical Oncology 2016”, https://lacuna.tiptreesystems.com/venue/journal-of-clinical-oncology/2016.
Top Authors
Impactful Papers
Papers from Journal of Clinical Oncology 2016 that shaped research clusters.
Influential
Papers
| Title |
|---|
| Age- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Analysis of BRCA1-related functional associations in sporadic triple negative breast cancer: A network-based approach. |
| A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohort |
| A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer. |
| A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer. |
| Behavioral, Social, and Emotional Symptom Comorbidities and Profiles in Adolescent Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study |
| Breast oncology precision medicine: Genomic testing and treatment at the population level. |
| Causal effects of methotrexate reductions/delays in treatment of high-grade resectable osteosarcoma. |
| Chemotherapy and radiotherapy in early stage uterine papillary serous and clear-cell carcinoma: A National Cancer Data Base study. |
| Clinical factors and the role of Wnt regulators in racial disparity of metastatic colorectal cancer survival. |
| Computerized textural analysis of DCE-MRI to enable identification of HER2-enriched breast cancers. |
| Detection of Occult Micrometastases in Patients With Clinical Stage I Non–Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance) |
| Efficacy and safety of rhLTα-Da with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-labelled, controlled, phase IIb trial. |
| Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 |
| Expanded criteria in men on active surveillance monitored by MRI-TRUS fusion biopsy. |
| Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III tri |
| Gene-expression signatures as prognostic for relapse in stage I testicular germ cell tumors (TGCT). |
| Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870). |
| Insomnia symptoms and memory problems in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study. |
| Missing the mark? Prostate cancer upgrading by systematic biopsy over fusion biopsy. |
| Multi-institutional evaluation of multiparametric MRI and fusion-guided prostate biopsy in a biopsy-naive population. |
| Patient-reported levels of concern in the Childhood Cancer Survivor Study (CCSS). |
| Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). |
| Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance. |
| Practice patterns and outcomes for hormone receptor positive and node negative breast cancer patients with intermediate risk Oncotype DX scores: Analysis of the National Cancer Database. |
| Predicting return of erectile function following external beam radiotherapy or brachytherapy for prostate cancer using EPIC-CP. |
| Prevalence of autoimmune comorbidities in patients with metastatic melanoma in the US. |
| Prognostic factors of advanced Hodgkin’s lymphoma: multivariate analysis of 199 Chinese patients with long-term follow-up. |
| Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter |
| Reply to R.L. Bowen et al, M. Froehner et al, J.L. Leow et al, and C. Brady et al |
| Serum microRNAs/enriched pathways in lung cancer 1-4 years before diagnosis: A pilot study from the HUNT Biobank, Norway. |
| Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target. |
| The changing utilization of neoadjuvant chemotherapy among different racial groups and its effect on mastectomy rates. |
| Tremelimumab, a monoclonal antibody against CTLA-4, in combination with subtotal ablation (trans-catheter arterial chemoembolization [TACE], radiofrequency ablation [RFA] or cryoablation) in patients |
| Tumor contact length: A novel multiparametric MRI predictor of prostate cancer outcomes. |
| Validation of a multi-marker panel for early detection of ovarian cancer. |